April 28, 2020
Antares Pharma Inc. again defeated a proposed securities class action alleging it misled investors about the risks of hypertension, suicide and depression associated with a testosterone medication after a New Jersey federal judge on Tuesday said the company's purported misrepresentations were "vague and general statements of optimism."
July 02, 2019
A New Jersey federal judge on Tuesday nixed a proposed securities class action against Antares Pharma Inc. after finding that a shareholder failed to back up his claims that the company made false and misleading statements about a testosterone medication.
July 27, 2018
A New Jersey federal judge on Friday appointed Pomerantz LLP and Lite DePalma Greenberg LLC as lead counsel and liaison counsel, respectively, and the firms' client as lead plaintiff in a putative securities class action against Antares Pharma Inc. over allegedly false and misleading statements about its testosterone medication.